

ICDF Update

Issue 2

24/11/2010

Keeping you informed

This newsletter is aimed at Consultant Oncologists/ Haematologists and other associated clinicians, commissioners and NHS managers who may be involved in accessing new cancer drugs.

To date 33 requests have been approved with a total spend of £400,000

Current Approved Drug Policies:

- Azacitidine
- Bevacizumab
- Cetuximab
- Everolimus
- Lapatinib
- Sorafenib

New Cancer Drug Policies

- Bevacizumab for Triple Neg Breast Cancer
- Imatinib for 'c-kit positive' Mucosal Melanoma

Briefing Session Friday 19th November

Representatives from PCTs and Provider Trusts across the region attended a briefing session on Friday 19th November to find out more about how to access the Interim Cancer Drug Fund. The session covered: The policy adopted in the West Midlands; The application process and role of the PCT; The Role of the ICDF Clinical Panel and a Question and Answer session

To ensure requests are processed as quickly as possible all supporting evidence/ research should be submitted with the application form

To make applications easier, the application form is now available as a word document on both the SHA and WMSCT's websites. To prevent any hold up, if waiting for signatures from Medical Director and/or Chemotherapy Lead within a Trust, a covering email can be sent stating permission has been granted. A hard copy/scan with appropriate signatures should then be submitted as soon as possible after the application.

All PCTs need to ensure that they have adopted the generic IFR policy for the West Midlands. If you have any queries regarding the process please email Mandy Matthews mandy.matthews@worcestershire.nhs.uk

New Drugs approved

Bevacizumab for Triple Neg Breast Cancer

Bevacizumab has been accepted, within its licensed indication by the ICDF Clinical Panel for funding under the interim cancer drugs fund as first line treatment for patients with advanced 'triple negative' breast cancer in combination with paclitaxel or docetaxel.

Imatinib for 'c-kit positive' Mucosal Melanoma

Imatinib has been accepted by the ICDF Clinical Panel for funding under the interim cancer drugs fund as treatment for patients with advanced mucosal melanoma carrying a mutation in 'c-kit'.

Use of these drugs outside of the stated eligibility criteria will only be considered in exceptional circumstances through the Individual Funding route.

If Clinicians wish the ICDF panel to consider a drug for a cohort policy they should submit a business case to the Chair of the Panel via wm.cancerdrugs@nhs.net

If your patient has been turned down for funding in the past and you can demonstrate that they would benefit from the treatment please submit an application to the ICDF for consideration.

To apply for patients to access the above drugs consultants need to download the [application form](#) (completing sections A & B as appropriate) and send back to wm.cancerdrugs@nhs.net

If you have any general queries email wm.cancerdrugs@nhs.net or call Janice Cunningham, on 0121 695 2374. The ICDF policy, application form and other supporting information can be found at: www.wmsc.nhs.uk and www.westmidlands.nhs.uk;